BCRX logo
BCRX NASDAQ US

BioCryst Pharmaceuticals, Inc. - Common Stock

Healthcare · Biotechnology Website · IPO Mar 1994
$9.02
▼ $-0.36 (-3.84%)
Vol 7.8M
5
Quality Score
fail
Mkt Cap
$1.6B
ROE
-328.8%
Margin
-1.5%
D/E
225.89
Beta
0.88
52W
$6–$11

Wall Street Consensus

16 analysts · Apr 2026
5
Strong Buy
10
Buy
1
Hold
0
Sell
0
Strong Sell
93.8%
Buy Rating

Price Chart

Similar Stocks

BEAM
Beam Therapeutics Inc
$2.8B
IRON
Disc Medicine Inc
$3.0B
KOD
Kodiak Sciences Inc
$1.7B
IMNM
Immunome Inc
$2.4B
SRPT
Sarepta Therapeutics Inc
$2.3B
GRAL
Grail Inc
$3.3B
RLAY
Relay Therapeutics Inc
$1.5B
MLYS
Mineralys Therapeutics Inc
$2.9B
SNDX
Syndax Pharmaceuticals Inc
$1.8B
DAWN
Day One Biopharmaceuticals Inc
$956.9M

About BioCryst Pharmaceuticals, Inc. - Common Stock

BioCryst Pharmaceuticals (BCRX) — біотехнологічна компанія, що розробляє та комерціалізує ліки для лікування рідкісних захворювань, де є значна незадоволена медична потреба. Компанія займає нішу на ринку орфанних препаратів, маючи унікальну платформу відкриття ліків на основі структури, що дозволяє швидко розробляти та виводити на ринок нові терапії. Їх ключова конкурентна перевага — це портфель затверджених продуктів та перспективних кандидатів, націлених на специфічні біологічні шляхи.

Earnings

Beat rate: 75.0%
Quarter EPS Est EPS Act Surprise
Dec 2025 $0.04 $0.01 $-0.03
Sep 2025 $0.04 $0.06 +$0.02
Jun 2025 $0.01 $0.04 +$0.03
Mar 2025 $-0.07 $0.00 +$0.07

Fundamentals Trend

Metric 2025-06-30 2025-09-02 2025-10-02 2025-11-03 2025-12-03 2026-01-02
ROE (TTM) — -328.8% -328.8% -328.8% -328.8% -328.8%
P/E (TTM) — — — — — —
Net Margin 3.1% -6.4% -6.4% -6.4% -1.5% -1.5%
Gross Margin 98.3% 97.0% 97.0% 97.0% 97.4% 97.4%
D/E Ratio — 225.89 225.89 225.89 225.89 225.89
Current Ratio 2.25 2.25 2.25 2.25 1.87 1.87

Key Ratios

ROA (TTM)
-1.9%
P/S (TTM)
2.74
P/B
13.9
EPS (TTM)
$-0.05
CF/Share
$-1.24
Rev Growth 3Y
+42.1%
52W High
$11.31
52W Low
$6.00
$6.00 52-Week Range $11.31

How does BCRX compare to Biotechnology peers?

Peer group: Micro-cap Biotechnology (All) · 528 companies

BCRX AAPG ABEO ABOS ABP

BCRX valuation vs Biotechnology peers

P/E ratio
—
▼ 0% below peers (18.8)
vs Peers
vs Industry
Undervalued
P/S ratio
2.7
▼ 79% below peers (12.9)
vs Peers
vs Industry
Undervalued
P/B ratio
13.9
▲ 464% above peers (2.5)
vs Peers
vs Industry
Overvalued
Div yield
—
▼ 0% below peers (0.0%)
vs Peers
vs Industry
Low yield

BCRX profitability vs Biotechnology peers

ROE
-328.8%
▼ 389% below peers (-67.3%)
vs Peers
vs Industry
Weak
Net margin
-1.5%
▲ 99% above peers (-286.8%)
vs Peers
vs Industry
Below avg
Gross margin
97.4%
▲ 24% above peers (78.6%)
vs Peers
vs Industry
Weak
ROA
-1.9%
▲ 96% above peers (-46.7%)
vs Peers
vs Industry
Top tier

BCRX financial health vs Biotechnology peers

D/E ratio
225.9
▼ 0% below peers (0.0)
vs Peers
vs Industry
High debt
Current ratio
1.9
▼ 58% below peers (4.4)
vs Peers
vs Industry
Low liquidity
Beta
0.9
▼ 9% below peers (1.0)
vs Peers
vs Industry
Less volatile

BCRX fundamentals radar

BCRX Peer median Industry

BCRX profitability vs leverage

Bubble size = market cap · X = net margin · Y = D/E ratio

BCRX vs peers: key metrics

Latest News

BioCryst (BCRX) Rallies 7.10% on Acquisition Buzz
Yahoo Finance · Mar 21
BioCryst Pharmaceuticals, Inc. (BCRX) A Good Stock To Buy Now?
Yahoo Finance · Mar 21